

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF DR. JASON NI AS SENIOR VICE PRESIDENT OF THE MEDICAL DEPARTMENT

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company announces that it has appointed Dr. Jason Ni (“**Dr. Ni**”), who has extensive experience in global drug development, as the senior vice president of the medical department. He will be responsible for the clinical non-oncology medical team, pharmacovigilance division, clinical quality division and other relevant work.

Dr. Ni has worked in the biopharmaceutical industry for over 20 years and has extensive experience and expertise in various aspects, such as clinical development, pharmacovigilance and clinical quality. Prior to joining the Company, Dr. Ni had worked in leading international pharmaceutical giants, including AstraZeneca, and several innovative biotechnology companies. He has abundant successful experience in different aspects, ranging from new drug clinical development to market approval. With his outstanding leadership, Dr. Ni successfully facilitated the approval of four global new drug applications (NDA) and clinical trial applications of various investigational new drugs (IND). He also has directly interacted with international regulatory institutions, such as the Food and Drug Administration of the United States (FDA) and the European Medicines Agency (EMA), and various international advisory committees. In addition, Dr. Ni has experience in the establishment of advanced clinical and pharmacovigilance systems as well as the audit of good clinical practice (GCP) of drugs.

Dr. Ni obtained a medical degree from the School of Medicine of Southeast University and a doctorate of medicine from the School of Medicine of Temple University. He received supplementary training in pharmaceutical business management at the Wharton School of the University of Pennsylvania, and epidemiology training at Drexel University.

The Board would like to express its warmest welcome to Dr. Ni for joining the Group.

By Order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, October 28, 2020

As at the date of this announcement, the Board of the Company comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Mr. XIE Ronggang and Dr. ZHOU Yi as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.